意大利Psocare注册研究:银屑病生物制剂治疗可及性的社会经济不平等
同时,低教育程度者重症银屑病(PASI>20)比例呈显著上升趋势,失业患者病情更重。研究揭示意大利银屑病药物处方存在社会经济不平等,高社会经济阶层更常使用昂贵的生物制剂。
要点
- 高教育程度及经理/专业人员职业与生物制剂处方独立相关。
- 低教育程度患者重症银屑病(PASI>20)比例呈显著上升趋势。
- 失业患者较其他职业类别更可能病情严重。
核心结论
- 意大利银屑病生物制剂处方存在社会经济不平等,高社会经济阶层更常使用昂贵生物制剂。
主要发现
- 多因素分析显示,受教育程度高于初中及以下以及职业为经理或专业人员是入组时接受生物制剂处方的独立因素。
- 分析显示重症银屑病(PASI>20)随教育程度降低呈显著上升趋势。
- 失业患者较其他职业类别更可能病情严重。
关键数值与推荐
- 重症银屑病定义为PASI评分>20。
临床怎么用
- 临床处方生物制剂时应关注患者社会经济因素,避免因教育或职业差异导致治疗可及性不平等。
- 对低教育程度及失业患者应加强病情评估,因其更可能病情严重。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited evidence is available on the impact of socioeconomic factors on drug prescriptions for psoriasis. OBJECTIVES: To investigate factors influencing prescription of conventional vs. biological treatment for patients with psoriasis, based on the Italian Psocare registry, with a special focus on socioeconomic factors. METHODS: This was a cross-sectional study evaluating the baseline data of patients included in the Psocare registry. All of the consecutive adult patients with a diagnosis of chronic plaque psoriasis or psoriatic arthritis who were prescribed a systemic treatment for psoriasis at participating centres were included in this study. Univariate and multivariate analyses of the baseline factors associated with a biologics prescription were performed. RESULTS: From September 2005 to September 2009, 12 838 patients were identified. A multivariate analysis revealed that, among other factors, completing a level of education higher than lower secondary school and being employed as a manager or a professional were independent factors associated with a biologics prescription at entry in the registry. Additional analyses on the association between these two variables and a severe psoriasis condition [Psoriasis Area Severity Index (PASI) score > 20] revealed a significantly increasing trend of severe disease towards lower educational attainment, while unemployed patients were more likely to have a more severe condition compared with the other categories of workers. CONCLUSIONS: We documented inequalities of drug prescriptions for psoriasis in Italy, with a trend towards a higher frequency of prescription for more expensive biologics in higher socioeconomic sectors of the population.
引用
- Naldi L, Cazzaniga S, Di Mercurio M, et al. Inequalities in access to biological treatments for psoriasis: results from the Italian Psocare registry. Br J Dermatol. 2017. PMID: 27973689. doi:10.1111/bjd.15234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。